Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

NCT01952080
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Calcium Chloride for Prevention of Uterine Atony During Cesarean

NCT03867383
View directory record Official record
Conditions
Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
Interventions
Calcium Chloride, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

NCT02909777
View directory record Official record
Conditions
Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
Interventions
CUDC-907
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Early Phase 1 Interventional

MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression

NCT00187941
View directory record Official record
Conditions
Transplantation, Renal, Immunosuppression
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 1, 2026, 11:06 PM EDT
Completed No phase listed Observational

Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage

NCT02866877
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Pharmacokinetic modeling
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 1, 2026, 11:06 PM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

NCT02138812
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY1161909, Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Santa Monica, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 1, 2026, 11:06 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

NCT01684956
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Intradermal injection, Subcutaneous injection
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vancomycin Dose Optimization in Obesity

NCT06601257
View directory record Official record
Conditions
Pharmacokinetics and Pharmacodynamics
Interventions
Vancomycin (IV)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

NCT04004611
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 1, 2026, 11:06 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01460134
View directory record Official record
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 3 Interventional

Study of Oral Morphine Sulfate Administration in Pediatric Subjects

NCT03429400
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Morphine Sulfate
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
2 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sheffield, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 2 Interventional

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

NCT02581657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PE0139 Injection, Placebo Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 3 Interventional

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

NCT05511922
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, Drug: KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471
View directory record Official record
Conditions
Pain
Interventions
VX-548, Midazolam, Digoxin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

NCT01049022
View directory record Official record
Conditions
Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039)
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 14 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003430
View directory record Official record
Conditions
Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
L-778,123
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects

NCT01591148
View directory record Official record
Conditions
Morbid Obesity
Interventions
propofol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Biomarkers Intervention Core

NCT05616585
View directory record Official record
Conditions
Biological Markers, Diet, Healthy, Metabolomics, Nutrition, Healthy
Interventions
Pharmacokinetic (PK)- Controlled Feeding Diet, Dose Response (DR)- Controlled Feeding Diet
Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

NCT01476189
View directory record Official record
Conditions
Healthy Subjects
Interventions
Experimental paracetamol formulation, Marketed paracetamol, Higher dose marketed paracetamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

NCT01916850
View directory record Official record
Conditions
Healthy
Interventions
LX4211 400 mg, LX4211 800 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 1, 2026, 11:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 1, 2026, 11:06 PM EDT